Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Cell Imaging System Emphasizes Speed and Sensitivity

By BiotechDaily International staff writers
Posted on 26 Dec 2012
The most recent version of a high-speed cell imaging system designed for both screening and research has now been released to the biotech and life science markets.

The GE Healthcare (Chalfont St. Giles, United Kingdom) IN Cell Analyzer 2200 is a high-speed, flexible, modular imaging system suitable for both investigative microscopy and automated high-content screening of organelles, cells, tissues, and whole organisms.

For screening applications a combination of proprietary optics, a choice of large or standard chip camera, and fast hardware and software autofocus capabilities deliver accurate, high-speed imaging. A bright light source reduces exposure times to further maximize speed without compromising image quality and cell health while the rapid image restoration options allow confocal-like images to be obtained.

A variety of innovative imaging features and a wide range of objectives (2 to 100 times) gives exceptional flexibility for real-time research use. The manual microscope mode allows manipulation of images at full size and resolution, in and out zoom capability, and manual settings adjustments (e.g., filters, objectives, and z-height).

The instrument can image a two-colored 96-well plate assay in about 150 seconds and a one-color 1,536 plate in less than 20 minutes. This speed is possible due to a bright, seven-wavelength solid-state light source and scientific-grade CMOS camera coupled with an optimized stage and efficient, easy-to-use control software. Furthermore, the system is designed to maximize the quantitative accuracy of captured images for any sample type, including image restoration for dim samples.

Related Links:

GE Healthcare



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: The five stages of biofilm development: (1) Initial attachment, (2) Irreversible attachment, (3) Maturation I, (4) Maturation II, and (5) Dispersion. Each stage of development in the diagram is paired with a photomicrograph of a developing P. aeruginosa biofilm. All photomicrographs are shown to same scale (Photo courtesy of Wikimedia Commons).

Ionic Liquids Disperse Bacterial Biofilms and Increase Antibiotic Susceptibility

The ionic liquid choline-geranate was shown to effectively eliminate the protective biofilm generated by bacteria such as Salmonella enterica and Pseudomonas aeruginosa and to significantly increase the... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.